Source/Disclosures
Source:

Healio Coverage

June 27, 2020
1 min read
Save

Top five ARVO articles from first round of presentations

Source/Disclosures
Source:

Healio Coverage

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Presentations from the virtual Association for Research in Vision and Ophthalmology meeting were released in May and June.

Coverage of the second set of presentations is ongoing at Healio/OSN, but here are the top five articles from the first release.

FDA policy turns away thousands of potential cornea donations each year

An FDA policy that automatically disqualifies men who have had sex with men in the preceding 5 years from donating corneas cost eye banks an estimated 1,600 donated corneas in 2018. Read more.

Novel IOL designed to improve image quality in periphery

A novel IOL, designed to control field curvature and reduce peripheral astigmatism, holds promise to provide superior image quality in the whole visual field. Read more.

STAIRWAY trial shows sustained efficacy of faricimab

Simultaneous neutralization of Ang-2 and VEGF-A with faricimab has the potential to reduce vascular destabilization in age-related macular degeneration, achieving sustained efficacy with a significantly lower frequency of administration as compared with ranibizumab. Read more.

Study shows dose-dependent efficacy of emixustat in Stargardt disease

The results of a phase 2 multicenter trial showed dose-dependent RPE65 inhibition efficacy of emixustat in patients with macular atrophy secondary to Stargardt disease. The 10 mg dose showed near-complete suppression of the rod b-wave recovery rate after photobleaching and was therefore selected for an ongoing phase 3 trial. Read more.

Two-year PANORAMA results affirm aflibercept efficacy for nonproliferative diabetic retinopathy

Two-year results of the PANORAMA study show consistently better results with intravitreal aflibercept injection vs. sham in moderately severe to severe nonproliferative diabetic retinopathy. Read more.